News | November 18, 2009

PET Perfusion Reimbursement to Increase in 2010

November 18, 2009 – The Centers for Medicaid and Medicare Services (CMS) recently announced it will increase the reimbursement for positron emission tomography (PET) cardiac procedures in 2010.

The final published rule maintains the assignment of all cardiac PET CPT codes to APC 0307 – PET myocardial perfusion imaging, with an increase in the payment for APC 0307 from $1,156.87 in 2009 to $1,432.87 in 2010 – a 24 percent increase from 2009. CMS’s Hospital Outpatient Prospective Payment System (HOPPS) and the 2010 payment rates for procedures continue to package payment for PET radiopharmaceuticals with payment for the imaging procedure (i.e. the nuclear medicine procedure ambulatory payment classifications (APC) payment rate).

The increased reimbursement makes it more economically feasible for groups to adopt cardiac PET, said officials at Bracco Diagnostics Inc., which supplies PET radiotracers. The company said the increase, combined with the current worldwide shortage of the Mo-99 isotope used in SPECT imaging, have created more compelling reasons for physicians and hospitals to implement PET for myocardial perfusion imaging.

PET also offers unique advantages that can be especially beneficial for difficult-to-image patients, including females, those who are obese or require pharmacologic stress testing, and patients with multivessel disease or who have had an equivocal SPECT MPI study.

The final rule established by CMS will be effective for services on or after Jan. 1, 2010.

For more information: www.braccoimaging.com, www.cms.hhs.gov/HospitalOutpatientPPS/HORD/list.asp#TopOfPage

Related Content

Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Overlay Init